Cholangitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CHL066 MIFTS: 51	Cholangitis Categories: Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Cholangitis

MalaCards integrated aliases for Cholangitis:

Name: Cholangitis ¹² ²⁹ ⁵⁵ ⁴⁴ ¹⁵ ⁷³

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the digestive system

Disorders of gallbladder, biliary tract and pancreas

Other diseases of biliary tract

Cholangitis

External Ids:

Disease Ontology ¹² DOID:9446

ICD10 ³³ K83.0

ICD9CM ³⁵ 576.1

MeSH ⁴⁴ D002761

NCIt ⁵⁰ C26718

SNOMED-CT ⁶⁸ 82403002

UMLS ⁷³ C0008311

Sources

Summaries for Cholangitis

Disease Ontology : ¹² A bile duct disease that is an inflammation of the bile duct.

MalaCards based summary : Cholangitis is related to sclerosing cholangitis, neonatal and cholangitis, primary sclerosing. An important gene associated with Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Influenza A and Human T-cell leukemia virus 1 infection. The drugs Vancomycin and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and colon, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Sources

Related Diseases for Cholangitis

Diseases in the Cholangitis family:

Acute Cholangitis

Chronic Cholangitis

Diseases related to Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 499)

#	Related Disease	Score	Top Affiliating Genes
1	sclerosing cholangitis, neonatal	34.1	CLDN1 DCDC2
2	cholangitis, primary sclerosing	33.4	ABCB4 ALB CFTR DLAT FUT2 GGT1
3	suppurative cholangitis	33.3	ABCB4 CRP DLAT TNF
4	sclerosing cholangitis	32.9	ABCB11 ABCB4 ALB CFTR CLDN1 DCDC2
5	primary biliary cirrhosis	32.3	ABCB4 ALB DLAT F2 GGT1 SP100
6	cholelithiasis	32.2	ABCB4 ALB GPT
7	cholecystitis	32.2	ABCB4 ALB F2 GPT
8	autoimmune pancreatitis	30.9	CA2 CFTR HLA-DRB1
9	hepatitis	30.8	CLDN1 F2 GGT1 GPT TNF
10	autoimmune hepatitis	30.8	DLAT F2 GGT1 GPT HLA-DRB1
11	choledocholithiasis	30.6	ABCB4 ALB F2 GPT
12	inflammatory bowel disease	30.4	ALB CRP HLA-B HLA-DRB1 IL6 TNF
13	acute pancreatitis	30.2	CFTR CRP IL6
14	acquired immunodeficiency syndrome	30.1	ALB HLA-B IL6 TNF
15	cholestasis	30.1	ABCB11 ABCB4 F2 GGT1 GPT
16	autoimmune disease	30.1	HLA-B HLA-DRB1 IL6 TNF
17	portal hypertension	30.0	ALB F2 GPT TNF
18	liver cirrhosis	29.9	ALB F2 GGT1 GPT
19	hepatitis c	29.9	CLDN1 GGT1 GPT TNF
20	echinococcosis	29.9	HLA-B HLA-DRB1 IL6 TNF
21	autoimmune gastritis	29.8	HLA-B IL6 TNF
22	angioimmunoblastic lymphadenopathy with dysproteinemia	29.8	IL6 TNF
23	pure red-cell aplasia	29.8	ALB HLA-B HLA-DRB1
24	gallbladder disease	29.7	ABCB4 CEACAM5 CFTR
25	hepatitis a	29.7	ALB F2 GPT TNF
26	hepatitis b	29.7	ALB F2 GGT1 GPT TNF
27	alveolar echinococcosis	29.7	HLA-B HLA-DRB1 TNF
28	intussusception	29.7	CFTR CRP IL6
29	infantile liver failure syndrome 1	29.7	ALB F2 GPT
30	complex regional pain syndrome	29.6	HLA-B IL6 TNF
31	liver disease	29.6	ABCB11 ABCB4 ALB DLAT F2 GGT1
32	cystitis	29.5	CRP IL6 TNF
33	kawasaki disease	29.5	ALB CRP IL6 TNF
34	nonalcoholic fatty liver disease	29.5	CRP GGT1 IL6 TNF
35	psoriatic arthritis	29.4	CRP HLA-B HLA-DRB1 IL6 TNF
36	gastroenteritis	29.4	ALB CRP FUT2 IL6 TNF
37	meningitis	29.4	ALB CRP IL6 TNF
38	cytomegalovirus infection	29.4	HLA-B IL6 TNF
39	obstructive jaundice	29.3	ALB CRP F2 GGT1 GPBAR1 GPT
40	purpura	29.3	CRP F2 IL6 TNF
41	acute cystitis	29.3	ALB CRP IL6
42	acute pyelonephritis	29.3	ALB CRP IL6
43	osteoporosis	29.2	ALB CA2 CRP IL6 TNF
44	myeloma, multiple	29.2	ALB CRP IL6 TNF
45	pyelonephritis	29.1	ALB CRP IL6 TNF
46	bacterial meningitis	29.1	ALB CRP IL6 TNF
47	biliary tract disease	29.1	ABCB11 ABCB4 ALB CEACAM5 F2 GGT1
48	leptospirosis	29.1	CRP F2 IL6 TNF
49	rheumatoid arthritis	29.0	CRP HLA-B HLA-DRB1 IL6 TNF
50	bile duct disease	29.0	ABCB11 ABCB4 ALB CEACAM5 F2 GGT1

Comorbidity relations with Cholangitis via Phenotypic Disease Network (PDN): (show all 17)

Acute Cystitis	Acute Pancreatitis
Biliary Tract Neoplasm	Cholecystitis
Cholestasis	Deficiency Anemia
Familial Atrial Fibrillation	Gallbladder Cancer
Heart Disease	Hepatitis
Intrahepatic Gall Duct Cancer	Pancreatic Cancer
Pancreatitis, Hereditary	Paralytic Ileus
Postcholecystectomy Syndrome	Primary Biliary Cirrhosis
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Cholangitis:

Sources

Symptoms & Phenotypes for Cholangitis

MGI Mouse Phenotypes related to Cholangitis:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.76	ABCB4 ALB CA2 CFTR F2 FUT2
2	homeostasis/metabolism	MP:0005376	9.73	ABCB11 ABCB4 ALB CA2 CFTR CLDN1
3	liver/biliary system	MP:0005370	9.17	ABCB11 ABCB4 ALB CFTR GPBAR1 IL6

Sources

Drugs & Therapeutics for Cholangitis

Drugs for Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vancomycin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1404-90-6

14969 441141

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Cefotaxime

Approved

Phase 4,Not Applicable

63527-52-6

456256 5742673

Ciprofloxacin

Approved, Investigational

Phase 4

85721-33-1

2764

Azithromycin

Approved

Phase 4

83905-01-5

55185 447043

Cefoxitin

Approved

Phase 4,Not Applicable

35607-66-0

441199

Imipenem

Approved

Phase 4

74431-23-5, 64221-86-9

104838

Epinephrine

Approved, Vet_approved

Phase 4

51-43-4

5816

Racepinephrine

Approved

Phase 4

329-65-7

838

Metronidazole

Approved

Phase 4,Phase 1,Not Applicable

443-48-1

4173

Mycophenolic acid

Approved

Phase 4,Phase 3,Phase 2

24280-93-1

446541

Prednisolone

Approved, Vet_approved

Phase 4,Not Applicable

50-24-8

5755

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2

104987-11-3

445643 439492

Methylprednisolone

Approved, Vet_approved

Phase 4,Not Applicable

83-43-2

6741

Methylprednisolone hemisuccinate

Approved

Phase 4,Not Applicable

2921-57-5

Prednisone

Approved, Vet_approved

Phase 4,Not Applicable

53-03-2

5865

Prednisolone phosphate

Approved, Vet_approved

Phase 4,Not Applicable

302-25-0

Ceftriaxone

Approved

Phase 4,Phase 2

73384-59-5

5479530 5361919

Ursodeoxycholic acid

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

128-13-2

31401

chenodeoxycholic acid

Approved

Phase 4,Phase 3,Phase 2

474-25-9

10133

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Temocillin

Approved, Investigational

Phase 4

66148-78-5

Leflunomide

Approved, Investigational

Phase 4

75706-12-6

3899

Aprepitant

Approved, Investigational

Phase 4

170729-80-3

6918365 151165

Palonosetron

Approved, Investigational

Phase 4

119904-90-4, 135729-61-2, 135729-56-5

148211

Fosaprepitant

Approved

Phase 4

172673-20-0

219090

Prednisolone hemisuccinate

Experimental

Phase 4,Not Applicable

2920-86-7

Substance P

Investigational

Phase 4

33507-63-0

44359816

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Not Applicable

Antitubercular Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Clavulanic Acids

Phase 4

Amoxicillin-Potassium Clavulanate Combination

Phase 4

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 1

Adrenergic beta-Agonists

Phase 4

Anti-Asthmatic Agents

Phase 4,Phase 1

Bronchodilator Agents

Phase 4,Phase 1

Mydriatics

Phase 4

Adrenergic alpha-Agonists

Phase 4

Sympathomimetics

Phase 4

Neurotransmitter Agents

Phase 4,Phase 2

Epinephryl borate

Phase 4

Autonomic Agents

Phase 4,Phase 1

Respiratory System Agents

Phase 4,Phase 2,Phase 1

Adrenergic Agents

Phase 4

Adrenergic Agonists

Phase 4

Vasoconstrictor Agents

Phase 4,Phase 2

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 268)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Unknown status	NCT02605213	Phase 4	Vancomycin;Placebo
2	Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis	Unknown status	NCT02057679	Phase 4	Amoxicillin clavulanic;Placebo
3	Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice	Unknown status	NCT00731419	Phase 4
4	Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis	Unknown status	NCT01820026	Phase 4	Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
5	Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis	Unknown status	NCT02839356	Phase 4	epinephrine;normal saline
6	Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture	Unknown status	NCT01125865	Phase 4
7	Balloon Catheter vs. Basket Catheter for Endoscopic Bile Duct Stone Extraction	Completed	NCT02909595	Phase 4
8	DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study	Completed	NCT01744847	Phase 4
9	Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction	Completed	NCT00280709	Phase 4
10	RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction	Completed	NCT00980889	Phase 4
11	A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.	Completed	NCT00545402	Phase 4	Mycophenolate mofetil, adjusted dose;Tacrolimus;Corticosteroids, IV;Mycophenolate mofetil, Standard dose;Corticosteroids, PO
12	Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents	Completed	NCT01315522	Phase 4
13	Antibiotics to Decrease Post ERCP Cholangitis	Recruiting	NCT03087656	Phase 4	Ceftriaxone;Levofloxacin
14	A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis	Recruiting	NCT03345589	Phase 4	18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
15	Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis	Recruiting	NCT02308111	Phase 4	Obeticholic Acid (OCA);Placebo
16	Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment	Recruiting	NCT03633227	Phase 4	Obeticholic Acid (OCA);Placebo
17	Temocillin Pharmacokinetics in Paediatrics	Recruiting	NCT02260102	Phase 4	Temocillin
18	Leflunomide for Maintenance of Remission in IgG4 Related Disease	Recruiting	NCT02703194	Phase 4	Prednisone;Leflunomide
19	A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis	Active, not recruiting	NCT02464020	Phase 4	Vancomycin
20	PALONOSETRON X FOSAPREPITANT IN PONV	Not yet recruiting	NCT03586817	Phase 4	Palonosetron;Fosaprepitant
21	The INFECIR-2 Albumin Prevention Study	Terminated	NCT02034279	Phase 4	Albumin
22	Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis	Unknown status	NCT01398917	Phase 3
23	Probiotics in Patients With Primary Sclerosing Cholangitis	Unknown status	NCT00161148	Phase 3	Probiotics
24	The Effect of Bezafibrate on Cholestatic Itch	Unknown status	NCT02701166	Phase 3	Bezafibrate;Placebo
25	Effect of Saline Irrigation to DEcrease Rate Of Residual Common Bile Duct Stones	Unknown status	NCT01425177	Phase 3
26	Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects	Completed	NCT01802073	Phase 3	Oral Vancomycin
27	Trial of High-dose Urso in Primary Sclerosing Cholangitis	Completed	NCT00059202	Phase 2, Phase 3	Ursodeoxycholic Acid
28	Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy	Completed	NCT02967926	Phase 3
29	Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients	Completed	NCT00622869	Phase 3	Tacrolimus (reduced tacrolimus);Tacrolimus (tacrolimus elimination);Tacrolimus (tacrolimus control);Everolimus (reduced tacrolimus);Everolimus (tacrolimus elimination);Corticosteroids
30	Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients	Completed	NCT01150097	Phase 3	Tacrolimus (reduced tacrolimus);Everolimus (reduced tacrolimus);Tacrolimus (tacrolimus elimination);Everolimus (tacrolimus elimination);Tacrolimus (tacrolimus control);Corticosteroids
31	A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Completed	NCT02550288	Phase 3	Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule
32	A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)	Completed	NCT02460159	Phase 3	EZ 10 mg/Atorva 20 mg FDC;EZ 10 mg/Atorva 10 mg FDC
33	A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)	Completed	NCT02741245	Phase 3	Ezetimibe 10 mg;Rosuvastatin 2.5 mg;Placebo for Ezetimibe;Placebo for Rosuvastatin
34	A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients	Completed	NCT01625377	Phase 3	tacrolimus;everolimus;Basiliximab;Mycophenolic Acid;Corticosteroids
35	Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)	Recruiting	NCT03602560	Phase 3	seladelpar 5-10 mg;seladelpar 10 mg;Placebo
36	Vancomycin for Primary Sclerosing Cholangitis	Recruiting	NCT03710122	Phase 2, Phase 3	Vancomycin
37	Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)	Recruiting	NCT03301506	Phase 2, Phase 3	Seladelpar 2 mg Capsule;Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
38	Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders	Recruiting	NCT02937012	Phase 3	Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
39	Kaffes Stent in the Management of Post-surgical Biliary Strictures	Recruiting	NCT03716232	Phase 3
40	Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation	Recruiting	NCT02584283	Phase 3	Glutathione
41	A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma	Recruiting	NCT02539537	Phase 3	Gemcitabine;Folinic Acid;5-Fluoro-uracil;Oxaliplatin;Irinotecan;L-folinic
42	Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer	Recruiting	NCT02170090	Phase 3	Gemcitabine;Cisplatin;Capecitabine
43	Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis	Active, not recruiting	NCT01473524	Phase 3	Obeticholic Acid (OCA);Placebo
44	Remaxol® in Malignant Mechanical Jaundice	Active, not recruiting	NCT03416062	Phase 3	Remaxol®;Ringer's Solution
45	Remaxol® in Mechanical Jaundice of Non-malignant Origin	Active, not recruiting	NCT03418935	Phase 3	Remaxol (succinate + methionine + inosine + nicotinamide);Ringer's Solution
46	Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease	Withdrawn	NCT03035058	Phase 3	Vedolizumab;Placebo
47	Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice	Unknown status	NCT01275768	Phase 1, Phase 2
48	Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis	Unknown status	NCT01690845	Phase 2
49	PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis	Completed	NCT02653625	Phase 2	Cenicriviroc 150 mg
50	Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP	Completed	NCT02098486	Phase 2	Moxifloxacin;ceftriaxone

Search NIH Clinical Center for Cholangitis

Cochrane evidence based reviews: cholangitis

Sources

Genetic Tests for Cholangitis

Genetic tests related to Cholangitis:

#	Genetic test	Affiliating Genes
1	Cholangitis ²⁹

Sources

Anatomical Context for Cholangitis

MalaCards organs/tissues related to Cholangitis:

⁴¹

Liver, T Cells, Colon, Thyroid, Testes, Lung, Neutrophil

Sources

Publications for Cholangitis

Articles related to Cholangitis:

(show top 50) (show all 2704)

#	Title	Authors	Year
1	Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. ( 30505677 )	Fadhel M...Asif A	2019
2	Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. ( 29380060 )	Hayashi M....Ohira H.	2018
3	Clinical guidelines for primary sclerosing cholangitis 2017. ( 29951926 )	Isayama H....Takikawa H.	2018
4	Mucinous cystic neoplasm of the liver with extrahepatic growth presenting with ascending cholangitis diagnosed by endoscopic ultrasound features: a case report. ( 29444709 )	Pattarapuntakul T....Sottisuporn J.	2018
5	The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )	Torres J....Hu J.	2018
6	Urgent endoscopic retrograde cholangiopancreatography is not superior to early ERCP in acute biliary pancreatitis with biliary obstruction without cholangitis. ( 29401491 )	Lee H.S....Chung J.B.	2018
7	Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept. ( 29754140 )	Popp F....Mueller R.B.	2018
8	Rituximab therapy in rheumatoid arthritis and primary biliary cholangitis. ( 29338925 )	Sargin G....Cildag S.	2018
9	Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )	Ricciuto A....Griffiths A.M.	2018
10	Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment. ( 29889683 )	Chen J....Wang X.	2018
11	Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. ( 29862092 )	Parekh R....Kaur N.	2018
12	Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis. ( 29922759 )	Friedrich K....Gotthardt D.N.	2018
13	Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )	Christensen B....Rubin D.T.	2018
14	Response to Re: Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. ( 29878697 )	Gomi H....Takada T.	2018
15	Primary Biliary Cholangitis and Autoimmune Hepatitis. ( 29751878 )	Gonzalez R.S....Washington K.	2018
16	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. ( 29320524 )	Zenouzi R....Lohse A.W.	2018
17	Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )	Nordenvall C....Bergquist A.	2018
18	Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. ( 29090868 )	Mayumi T....Yamamoto M.	2018
19	Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial. ( 29790196 )	Khanna A....Jones D.E.	2018
20	Congestive Heart Failure as a Differential Diagnosis of Cholangitis. ( 29716822 )	Jolobe O.M.P.	2018
21	Lack of Correlation of Liver Tests With Fibrosis Stage at Diagnosis in Pediatric Primary Sclerosing Cholangitis. ( 29356767 )	Cotter J.M....Mack C.L.	2018
22	Outcomes Associated With Timing of ERCP in Acute Cholangitis Secondary to Choledocholithiasis. ( 29356786 )	Parikh M.P....Sanaka M.R.	2018
23	A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis? ( 29316057 )	Ferrari F....Iorio R.	2018
24	The role of MRI and ERCP in the evaluation of disease activity and severity in primary sclerosing cholangitis. ( 29901259 )	Tenca A....FAorkkilAo M.	2018
25	Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. ( 29969801 )	Kuraoka N....Horio Y.	2018
26	Peribiliary Cysts presenting as Primary Sclerosing Cholangitis. ( 29432923 )	Tamilarasan A.G....Lee A.U.	2018
27	Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. ( 29090866 )	Gomi H....Yamamoto M.	2018
28	Cholangitis complicated by infection of a simple hepatic cyst. ( 29948816 )	Mizumoto Y....Koike K.	2018
29	Re: Acute cholangitis: current concepts. ( 29392900 )	Yuen B.H.M....Stewart G.	2018
30	Clinical applicability of Tokyo guidelines 2018/2013 in diagnosis and severity evaluation of acute cholangitis and determination of a new severity model. ( 29374984 )	Gravito-Soares E....TomAc L.	2018
31	Progress in Primary Biliary Cholangitis. ( 29874531 )	Carey E.J.	2018
32	Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314130 )	Tao P....Wang S.Y.	2018
33	Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )	Rao B.B....Kowdley K.V.	2018
34	Cholangitis secondary to afferent loop syndrome from a gastric stump adenocarcinoma. ( 29620408 )	Valdivielso CortA!zar E....Alonso-Aguirre P.	2018
35	Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept. ( 29854373 )	Rendina M....Di Leo A.	2018
36	Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence inA situ hybridization using transpapillary forceps biopsy specimens. ( 29532638 )	Kato A....Joh T.	2018
37	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. ( 29874528 )	Corpechot C....Poupon R.	2018
38	Shorter Duration of Antibiotic Treatment for Acute Bacteraemic Cholangitis with Successful Biliary Drainage:A Retrospective Cohort Study. ( 29408612 )	Doi A....Iwata K.	2018
39	Endoscopic diagnosis and treatment of biliary obstruction due to acute cholangitis and acute pancreatitis secondary to Fasciola hepatica infection. ( 29350372 )	Dolay K....AkAsakaya A.	2018
40	Endoscopic management of primary sclerosing cholangitis. ( 29883229 )	Tabibian J.H....Baron T.H.	2018
41	Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. ( 29808485 )	Tse C.S....Lightner A.L.	2018
42	Percutaneous cholecystostomy for high-risk patients with acute cholangitis. ( 29742738 )	Li Y.L....Lee P.S.	2018
43	Kindler syndrome in a patient with colitis and primary sclerosing cholangitis: coincidence or association? ( 29634879 )	Roda A.8....Has C.	2018
44	Successful treatment of<i>Providencia rettgeri</i>cholecystitis and neutrophilic cholangitis in a cat. ( 29399368 )	Newton P.L....Fry D.R.	2018
45	NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population. ( 29795304 )	Nishida N....Nakamura M.	2018
46	Tokyo Guidelines 2018: updated Tokyo Guidelines for the management of acute cholangitis/acute cholecystitis. ( 29334699 )	Takada T.	2018
47	Increased Risk for Hip Fractures among Patients with Cholangitis: A Nationwide Population-Based Study. ( 29967788 )	Hsu C.C....Kuo S.J.	2018
48	Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases. ( 29313399 )	Mo Z....Zeng Q.	2018
49	Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. ( 29781738 )	Taghavi S.A....Bagheri Lankarani K.	2018
50	Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. ( 29977030 )	Mosher V.A.L....Goodyear B.G.	2018

Sources

Genes for Cholangitis

Genes related to Cholangitis (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CLDN1	Claudin 1	Protein Coding	50.15	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
2	DCDC2	Doublecortin Domain Containing 2	Protein Coding	41.27	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
3	DLAT	Dihydrolipoamide S-Acetyltransferase	Protein Coding	31.45	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19094117
4	ABCB4	ATP Binding Cassette Subfamily B Member 4	Protein Coding	30.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17539998 15258199
5	CFTR	Cystic Fibrosis Transmembrane Conductance Regulator	Protein Coding	24.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10094942
6	CA2	Carbonic Anhydrase 2	Protein Coding	24.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7768386 9605187 15026266 (more) 17023884
7	ALB	Albumin	Protein Coding	23.21	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	GPBAR1	G Protein-Coupled Bile Acid Receptor 1	Protein Coding	22.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	SP100	SP100 Nuclear Antigen	Protein Coding	22.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	22.43	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15765973 12424566
11	CRP	C-Reactive Protein	Protein Coding	22.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	TNF	Tumor Necrosis Factor	Protein Coding	22.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	F2	Coagulation Factor II, Thrombin	Protein Coding	22.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	FUT2	Fucosyltransferase 2	Protein Coding	21.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	IL6	Interleukin 6	Protein Coding	21.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	ABCB11	ATP Binding Cassette Subfamily B Member 11	Protein Coding	21.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	21.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	GGT1	Gamma-Glutamyltransferase 1	Protein Coding	13.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion Molecule 5	Protein Coding	11.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	HP	Haptoglobin	Protein Coding	11.68	DISEASES inferred ¹⁵ GeneCards inferred via : Summaries (show sections)
22	PRTN3	Proteinase 3	Protein Coding	11.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Cholangitis

Sources

Expression for Cholangitis

Search GEO for disease gene expression data for Cholangitis.

Sources

Pathways for Cholangitis

Pathways related to Cholangitis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.49	HLA-B HLA-DRB1 IL6 SP100 TNF
2	Human T-cell leukemia virus 1 infection ³⁷	12.14	HLA-B HLA-DRB1 IL6 TNF
3	Epstein-Barr virus infection ³⁷	11.97	HLA-B HLA-DRB1 IL6 TNF
4	Hematopoietic cell lineage ³⁷	11.64	HLA-DRB1 IL6 TNF
5	Rheumatoid arthritis ³⁷	11.59	HLA-DRB1 IL6 TNF
6	Selenium Micronutrient Network ¹ Show member pathways Folate Metabolism ¹ Metabolism of ingested MeSeO2H into MeSeH ⁶⁶ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	11.43	ALB CRP F2 GGT1 IL6 TNF
7	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.15	CA2 IL6 TNF
8	Bile secretion ³⁷	11.11	ABCB11 ABCB4 CA2 CFTR
9	Cytokines and Inflammatory Response ¹	10.9	HLA-DRB1 IL6 TNF
10	Overview of nanoparticle effects ¹	10.61	CRP IL6 TNF

Sources

GO Terms for Cholangitis

Cellular components related to Cholangitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.8	ABCB11 ABCB4 CEACAM5 CFTR CLDN1 HLA-B
2	extracellular space	GO:0005615	9.76	ALB CA2 CRP F2 GGT1 GPT
3	extracellular exosome	GO:0070062	9.36	ABCB11 ABCB4 ALB CA2 CEACAM5 F2
4	intercellular canaliculus	GO:0046581	8.96	ABCB11 ABCB4

Biological processes related to Cholangitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	defense response to Gram-positive bacterium	GO:0050830	9.5	CRP IL6 TNF
2	interferon-gamma-mediated signaling pathway	GO:0060333	9.43	HLA-B HLA-DRB1 SP100
3	positive regulation of neuroinflammatory response	GO:0150078	9.16	IL6 TNF
4	acute-phase response	GO:0006953	9.13	CRP F2 IL6
5	negative regulation of lipid storage	GO:0010888	8.8	CRP IL6 TNF

Molecular functions related to Cholangitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ATPase activity, coupled to transmembrane movement of substances	GO:0042626	8.8	ABCB11 ABCB4 CFTR

Sources

Sources for Cholangitis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia